#3901 Phospho-Bcr (Tyr177) Antibody
|
CSTコード | 包装 | 希望納入価格 (円) |
||
---|---|---|---|---|
#3901S | 100 μL | 66,000 | ログインすると国内在庫状況がご確認いただけます。
|
感度 | 分子量 (kDa) | 抗体の由来 | 貯法 | |
---|---|---|---|---|
内在性 | 160 (Bcr); 210 (Bcr-Abl) | Rabbit | -20℃ |
種交差性 (社内試験済) | |
---|---|
ヒト、マウス | - |
ウェスタンブロッティング (1:1000)、フローサイトメトリー (1:100)
特異性・感度 | |
---|---|
内在性レベルのTyr177 がリン酸化されたBcr、Bcr-Abl タンパク質を検出します。 |
使用抗原 | |
---|---|
ヒトのBcr タンパク質のTyr177 周辺領域 (合成リン酸化ペプチド) |
ホモロジー (相同性) 検索をご希望の場合 >>>
ホモロジー検索をご要望の際は、ご希望のサンプル種のアミノ酸配列とともにお問合せください。
社内データ |
---|
※下記の社内データは、すべて3901 の推奨プロトコールで実験した結果です。
Western Blotting

Western blot analysis of extracts from K562 cells, untreated or calf intestinal phosphatase (CIP)-treated, using Phospho-Bcr (Tyr177) Antibody (upper) or Bcr Antibody #3902 (lower).
Western Blotting

Western blot analysis of extracts from PAE/CKR cells (expressing chimeric receptors of the extracellular domain of CSF-1R, and transmembrane and cytoplasmic domains of KDR) stimulated with CSF-1 (40 ng/ml for 5 minutes) or NIH/3T3 cells stimulated with PDGF (40 ng/ml for 2 minutes) using Phospho-Bcr (Tyr177) Antibody (upper) or Bcr Antibody #3902 (lower).
Flow Cytometry

Flow cytometric analysis of K562 cells, untreated (green) or Gleevec® (STI571)- treated (blue), using Phospho-Bcr (Tyr177) Antibody compared to a nonspecific negative control antibody (red).
バックグラウンド |
---|
The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain, and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region may be involved in a GTPase activating function for the small GTP-binding protein Rac (2,3). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator (4). Research studies have shown that the Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyr177 of Bcr is phosphorylated in the Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl (6). Phosphorylated Tyr177 provides a docking site for Gab2 and GRB2 (7,8).
- Groffen, J. et al. (1984) Cell 36, 93-99.
- Maru, Y. et al. (1991) Cell 67, 459-468.
- Che, W. et al. (2001) Circulation 104, 1399-1406.
- Abe, J. I. et al. (2001) Ann. N.Y. Acad. Sci. 947, 341-343.
- Voncken, J. W. et al. (1995) Cell 80, 719-728.
- He, Y. et al. (2002) Blood 99, 2957-2968.
- Sattler, M. et al. (2002) Cancer Cell 1, 479-492.
- Warmuth, M. et al. (1995) J. Biol. Chem. 272, 33260-33270.
使用例 |
---|
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
本製品は試験研究用です。